Boston Scientific Corp
(MIL:1BSX)
€
85.5
0 (0%)
Market Cap: 126.98 Bil
Enterprise Value: 135.61 Bil
PE Ratio: 74.26
PB Ratio: 6.39
GF Score: 56/100 Boston Scientific Corp at Stifel Virtual Healthcare Conference Transcript
Nov 18, 2020 / 01:40PM GMT
Frederick Allen Wise
Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Equity Research Analyst
Good morning, everybody, and welcome to Day 3 of the Stifel Healthcare Conference. I'm really pleased and glad to welcome Boston Scientific: Joe Fitzgerald, Executive Vice President and President of the Interventional Cardiology Division; Dan Brennan, EVP and Chief Financial Officer; Susie Lisa, Head of Investor Relations. This is a particularly timely discussion this morning given yesterday's announcement about the company's LOTUS TAVR valve, the decision to stop that program and focus on other growth platforms.
But in no particular order, first of all, welcome to all of you. Thank you for being here. Really appreciate it.
Daniel J. Brennan
Boston Scientific Corporation - Executive VP & CFO
Thanks, Rick. Thanks for the invitation. Pleasure to be here.
Frederick Allen Wise
Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Equity Research Analyst
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot